The Liver Meeting Digital Experience™ (TLMdX)

Think twice before withdrawing HBV treatment. Not all patients can safely discontinue nucleos(t)ide analogue (NA) therapy as shown in the retrospective RETRACT-B study of patients from Europe, North America, and Asia.

Increased serum iron or transferrin saturation levels in individuals with non-alcoholic fatty liver disease (NAFLD) may point to an increased risk of hepatocellular carcinoma (HCC), according to a study presented at The Liver Meeting Digital Experience™.

Switching to tenofovir alafenamide (TAF) from nucleos(t)ide analogue therapies was associated with improved virologic response and liver function in patients with chronic hepatitis B virus (HBV) infection, even in those with decompensated HBV cirrhosis, according to real-world studies presented at AASLD 2021.

The pan-PPAR* agonist lanifibranor further advances into the NASH** treatment field, as more data from the phase IIb NATIVE*** study presented at AASLD 2021 unveil further histologic and therapeutic benefits for patients with NASH.

Non-overweight patients with non-alcoholic fatty liver disease (NAFLD) have an elevated risk of all-cause mortality following liver transplant and are also more likely to be removed from the liver transplant waitlist compared with obese/overweight patients, according to a study presented at The Liver Meeting Digital Experience™.

Statins can help preserve liver function in patients with chronic liver disease, according to two studies presented at AASLD 2021— showing that not only are statins protective for the heart, but also for the liver.

Access to liver transplantation suffers from a persistent and unacceptable gender gap, with female candidates on the wait list being much less likely to receive a transplant and facing a higher risk of dying than their male counterparts, according to an expert.

A liquid biopsy platform that utilizes protease biosensors can detect nonalcoholic steatohepatitis with pinpoint accuracy in both mice and humans.